Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P130013/S083

WATCHMAN FLX Pro Left Atrial Appendage Closure Device with Delivery System

Boston Scientific Corp · Decision date Feb 12, 2026

FDA DECISIONP130013/S083

What did the FDA decide?

FDA records P130013/S083 as a supplement to PMA P130013, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 12, 2026.

FDA approval order statement

introduction of an alternate radiopaque (RO) marker crimper system to be used in addition to the existing crimper system for manufacturing the WATCHMAN FLX Pro Left Atrial Appendage Closure Device with Delivery System
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Feb 12, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P130013/S083
Regulatory pathway
PMA supplement
Product code
NGV
Decision code
OK30
Decision date
Feb 12, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, appendage closure, left atrial.

Product code
NGV
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P130013/S077 · Related supplement

    WATCHMAN LEFT ATRIAL APPENDAGE (LAA) CLOSURE TECHNOLOGY

  2. P130013/S081 · Related supplement

    WATCHMAN FLX Pro Left Atrial Appendage Closure Device with Delivery System; WATCHMAN FLX Left Atrial Appendage Closure D

  3. P130013/S080 · Related supplement

    WATCHMAN FLX Left Atrial Appendage (LAA) Closure Device with Delivery System; WATCHMAN FLX Pro Left Atrial Appendage (

  4. P130013/S078 · Related supplement

    WATCHMAN FLX Pro Left Atrial Appendage Closure Device with Delivery System

  5. P130013/S079 · Related supplement

    WATCHMAN FLX Pro Left Atrial Appendage Closure Device with Delivery System

  6. P130013/S082 · Related supplement

    WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device with Delivery System; WATCHMAN FLX Pro Left Atrial Appendage Cl

  7. P130013/S083 received

    Application receipt date recorded by FDA.

  8. P130013/S083 · FDA decision

    30-Day Notice

  9. P130013/S076 · Related supplement

    WATCHMAN LEFT ATRIAL APPENDAGE (LAA) CLOSURE TECHNOLOGY

  10. P130013/S085 · Related supplement

    WATCHMAN FLXTM Left Atrial Appendage Closure Device with Delivery System; WATCHMAN FLXTM Pro Left Atrial Appendage Closu

  11. P130013/S084 · Related supplement

    WATCHMAN FLX Left Atrial Appendage Closure Device with Delivery System; WATCHMAN FLX Pro Left Atrial Appendage Closure

  12. P130013/S086 · Related supplement

    WATCHMAN FLX Left Atrial Appendage Closure Device with Delivery System; WATCHMAN FLX Pro Left Atrial Appendage Closure

  13. P130013/S089 · Related supplement

    WATCHMAN FLX Left Atrial Appendage Closure Device with Delivery System WATCHMAN FLX Pro Left Atrial Appendage Closure D

  14. P130013/S090 · Related supplement

    WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device with Delivery System; WATCHMAN FLX Pro Left Atrial Appendage Cl

Timeline entries are records held by MedtechLedger for P130013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P130013

Product / regulatory recordCompanyPathwayDecision dateSource
Boston Scientific CorpPMA supplementSep 4, 2025FDA
Boston Scientific CorpPMA supplementNov 6, 2025FDA
Boston Scientific CorpPMA supplementDec 12, 2025FDA
Boston Scientific CorpPMA supplementDec 15, 2025FDA
Boston Scientific CorpPMA supplementDec 15, 2025FDA
Boston Scientific CorpPMA supplementDec 18, 2025FDA
Boston Scientific CorpPMA supplementMar 25, 2026FDA
Boston Scientific CorpPMA supplementApr 23, 2026FDA
Boston Scientific CorpPMA supplementMay 18, 2026FDA
Boston Scientific CorpPMA supplementJul 21, 2026FDA
Boston Scientific CorpPMA supplementAug 21, 2026FDA
Boston Scientific CorpPMA supplementAug 28, 2026FDA

Explore the linked device profile

Other records with product code NGV

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT MEDICALPMA supplementAug 28, 2026FDA
ABBOTT MEDICALPMA supplementMay 28, 2026FDA
ABBOTT MEDICALPMA supplementMar 19, 2026FDA
ABBOTT MEDICALPMA supplementFeb 24, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corp

Headquarters
Not reported
FDA applicant address
One Scimed Pl., Maple Grove, MN, 55311

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records